Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (29)	8/7/2001 4:58:07 PM
From: nigel bates	Respond to of 123

Missed this (from website) ... Embargoed for release at 12:00 noon GMT 12 July, 2001 CELLTECH OUTLINES CDP 870 PHASE II RESULTS IN RHEUMATOID ARTHRITIS Celltech Group plc announced today outline preliminary results from a recently completed Phase II study with CDP 870, in rheumatoid arthritis (RA) patients. Celltech and Pharmacia Corporation are developing CDP 870 as a new treatment for rheumatoid arthritis and Crohn's disease. The dose-ranging Phase II study involved 203 patients, who were treated monthly for three months. They did not concurrently receive methotrexate or other immunomodulatory drugs. Dose-related benefit was observed, as assessed by the numbers of patients attaining American College of Rheumatology (ACR) scores. The following results were obtained after three months' treatment at the 400mg dose, administered once monthly by subcutaneous injection: • ACR20: 72% • ACR50: 48% • ACR70: 32% No safety issues were identified. Phase III studies of CDP870 in RA are expected to begin in early 2002. More details of the CDP 870 clinical programme will be discussed at Pharmacia's investor meeting in November 2001. Further Phase II studies in Crohn's disease, which are being conducted by Celltech, are ongoing. Dr. Peter Fellner, Chief Executive Officer of Celltech, commented: "These pleasing results provide us with confidence in proceeding to late-stage clinical studies with CDP870".